復星醫藥(600196.SH):子公司擬450萬元受讓易研雲100%股權
格隆匯 9 月 17日丨復星醫藥(600196.SH)公佈,2020年9月17日,控股子公司復星醫藥產業與關聯方復星健控簽訂《股權轉讓協議》,復星醫藥產業擬出資人民幣450萬元受讓復星健控持有的易研雲100%的股權(對應人民幣1000萬元認繳出資額,其中復星健控已實繳人民幣450萬元)。此次交易完成後,復星醫藥產業將持有易研雲100%的股權。此次交易的轉讓價格基於復星健控已實繳易研雲註冊資本的金額確定。
易研雲成立於2018年11月,註冊地為中國上海市,法定代表人為張威先生。易研雲的經營範圍包括醫療科技、生物科技、計算機科技、網絡科技、信息科技領域內的技術開發、技術轉讓、技術諮詢、技術服務、技術交流、技術推廣,企業管理、市場營銷策劃,大數據服務,翻譯服務,會議及展覽服務,軟件開發,信息諮詢服務(不含許可類信息諮詢服務),專業設計服務,機械設備、電子專用材料的研發,辦公用品、計算機、軟件及輔助設備的銷售[除依法須經批准的項目外,憑營業執照依法自主開展經營活動]。截至公告日,易研雲的註冊資本為人民幣1000萬元,其中:復星健控認繳註冊資本人民幣1000萬元、實繳註冊資本人民幣450萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.